Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, P.R. China.
Department of Research, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, P.R. China.
Mol Diagn Ther. 2020 Aug;24(4):433-441. doi: 10.1007/s40291-020-00469-4.
Interferon (IFN)-induced transmembrane protein 1 (IFITM1), a member of the IFN-induced transmembrane protein family, is reported to be highly expressed in tumor tissues as well as cancer cell lines, and it is an independent prognostic biomarker for patients with certain tumor types, such as gallbladder carcinoma, esophageal adenocarcinoma, colorectal cancer, and gastric cancer. Moreover, overexpression of IFITM1 promotes tumor cell proliferation, invasion, metastasis, angiogenesis, and therapeutic resistance, including endocrine therapy, chemotherapy, and radiotherapy resistance. Due to these diverse functions of IFITM1 in tumors, targeting IFITM1 may provide a novel strategy for cancer treatment and be highly desirable to improve cancer patient outcomes. Herein, we decipher the role of IFITM1 in cancer in detail.
干扰素诱导跨膜蛋白 1(IFITM1)是干扰素诱导跨膜蛋白家族的一员,据报道在肿瘤组织和癌细胞系中高度表达,是某些肿瘤类型(如胆囊癌、食管腺癌、结直肠癌和胃癌)患者的独立预后生物标志物。此外,IFITM1 的过表达促进肿瘤细胞增殖、侵袭、转移、血管生成和治疗耐药性,包括内分泌治疗、化疗和放疗耐药性。由于 IFITM1 在肿瘤中的这些多样化功能,靶向 IFITM1 可能为癌症治疗提供一种新策略,高度期望改善癌症患者的预后。在此,我们详细阐述 IFITM1 在癌症中的作用。